RBC Capital raised the firm’s price target on ResMed (RMD) to $300 from $294 and keeps an Outperform rating on the shares. The company delivered a strong Q4 result which beat consensus expectations across all key line items, and management provided FY26 gross margin guidance well ahead of RBC and consensus estimates, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMD: